ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Accepts sNDA Of NURTEC ODT for Preventive Treatment of Migraine americanpharmaceuticalreview
October 21, 2020Biohaven Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC? ODT (rimegepant) for the preventive treatment of migraine. -
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment americanpharmaceuticalreview
March 18, 2020Catalent welcomed the announcement by Biohaven the U.S. Food and Drug Administration (FDA) has approved its NURTEC? ODT (rimegepant) for the acute treatment of migraine in adults. -
Biohaven Wins FDA Approval for NURTEC ODT contractpharma
March 18, 2020Developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology.
Pharma Sources Insight January 2025
